Market Analysis
ImmunityBio Surges as Anktiva Drives 671% Revenue Growth
IBRX extended its rally after the company posted explosive 671% revenue growth, fueled by rising demand for its bladder cancer drug, Anktiva.
Total Stories
4
News
Anktiva
Section
Anktiva
Market Analysis
Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing
ImmunityBio (IBRX) stock jumped over 6% in premarket trading after the NCCN added ANKTIVA to its bladder cancer guidelines, expanding its use.
Market Analysis
Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva
ImmunityBio stock surged more than 20% after the European Commission granted conditional approval for its bladder cancer treatment, Anktiva.
Earnings
Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months
In the last three months, this biotech stock outperformed Nvidia (NVDA) by over 3x.